ARADIGM CORP. ARDM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tadsamillionaire who wrote (173)	8/28/2003 12:35:07 AM
From: Tadsamillionaire	of 255

AERx® iDMS (NN1998) Indication: Type 1 and 2 diabetes Phase: Phase 3 A pulmonary delivery system for the administration of insulin by inhalation. AERx® iDMS is being developed for the treatment of diabetes in collaboration with Aradigm Corporation. The AERx system includes a breath guidance system that guides patients to breathe optimally and reproducibly. Only when breathing is correct is the drug automatically administered. This feature is not found in any other technology and is the subject of several Aradigm patents. Importantly, the technology developed by Aradigm uses strips with insulin in liquid form and not in powder form as is the case with the technology from Inhale. This makes dose adjustment possible to the nearest unit just as with injections - something that does not appear to be possible with powders. The mean system efficiency/bioeffectiveness for the AERx system in studies involving patients with type 1 and type 2 diabetes has been shown to range between 13 and 17%, depending on the study design. Visit Aradigm at www.aradigm.com novonordisk.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next